Prostatic Cancer Clinical Trial
— UROCOROfficial title:
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
| Verified date | December 2012 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Spain: Ethics CommitteeSpain: Spanish Agency of Medicines |
| Study type | Observational |
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months
| Status | Completed |
| Enrollment | 197 |
| Est. completion date | December 2012 |
| Est. primary completion date | December 2012 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment - Provision of informed consent prior to conducting any study-related procedure Exclusion Criteria: - Patient involved in a Clinical Trial |
Observational Model: Cohort, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| Spain | Research Site | Albacete | |
| Spain | Research Site | Alcala de Henares | Madrid |
| Spain | Research Site | Antequera | Malaga |
| Spain | Research Site | Aranda de Duero | Burgos |
| Spain | Research Site | Baracaldo | Vizcaya |
| Spain | Research Site | Barcelona | |
| Spain | Research Site | Bilbao | Vizcaya |
| Spain | Research Site | Calatayud | Zaragoza |
| Spain | Research Site | Cordoba | |
| Spain | Research Site | Coslada | Madrid |
| Spain | Research Site | El Ejido | Almeria |
| Spain | Research Site | El Hospitalet de Llobregat | Barcelona |
| Spain | Research Site | Ferrol | Coru?a |
| Spain | Research Site | Galdakao | Vizcaya |
| Spain | Research Site | Granada | |
| Spain | Research Site | Guadalajara | |
| Spain | Research Site | Huercal Overa | Almeria |
| Spain | Research Site | Jaen | |
| Spain | Research Site | Logrono | La Rioja |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Majadahonda | Madrid |
| Spain | Research Site | Merida | Badajoz |
| Spain | Research Site | Miranda de Ebro | Burgos |
| Spain | Research Site | Monforte (casco Urbano) | Lugo |
| Spain | Research Site | Osuna | Sevilla |
| Spain | Research Site | Palma de Mallorca | Illes Balears |
| Spain | Research Site | Reus | Tarragona |
| Spain | Research Site | Sabadell | Barcelona |
| Spain | Research Site | San Sebastian | Guipuzcoa |
| Spain | Research Site | San Sebastian de Los Reyes | Madrid |
| Spain | Research Site | Toledo | |
| Spain | Research Site | Vigo | Pontevedra |
| Spain | Research Site | Zaragoza |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Metabolic syndrome | 3 months | No | |
| Primary | Metabolic syndrome | 6 months | No | |
| Primary | Metabolic syndrome | 12 months | No | |
| Primary | Diabetes | 3 months | No | |
| Primary | Diabetes | 6 months | No | |
| Primary | Diabetes | 12 months | No | |
| Secondary | Fracture Risk Assessment Tool (FRAx) assessment | 0 and 12 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01086956 -
Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy
|
N/A | |
| Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02687308 -
Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique
|
N/A | |
| Completed |
NCT04421781 -
Salvage HIFU for Local Recurrence in the Prostatic Bed After Prostatectomy and External Beam Radiation Therapy : Preliminary Results
|
||
| Recruiting |
NCT05740956 -
A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Enrolling by invitation |
NCT03173924 -
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05851521 -
To Evaluate LUTS and Complications Between Indwelling Catheter and Temporary Prostatic Stent in Patients Undergoing Minimally Invasive Procedures for the Treatment of Localized Prostate Cancer or Benign Prostatic Hyperplasia (HERMES)
|
N/A | |
| Completed |
NCT01998685 -
Prothrombotic Factors and Anaesthesia in Prostate Cancer
|
N/A | |
| Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 | |
| Terminated |
NCT03606889 -
Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia
|
N/A | |
| Completed |
NCT03481816 -
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
|
Phase 1 | |
| Completed |
NCT01171729 -
Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05623878 -
68Ga-labeled NY108 PET Imaging in Patients
|
Early Phase 1 | |
| Not yet recruiting |
NCT05184790 -
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology
|
||
| Completed |
NCT02564120 -
North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)
|
||
| Active, not recruiting |
NCT01787630 -
To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy
|
Phase 2/Phase 3 | |
| Terminated |
NCT02349139 -
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
|
Phase 1 |